Trial Profile
A Pilot Study of Personalized Biomarker-based Treatment Strategy or Immunotherapy in Patients With Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2023
Price :
$35
*
At a glance
- Drugs Afatinib (Primary) ; Durvalumab (Primary) ; Monalizumab (Primary) ; Niraparib (Primary) ; Palbociclib (Primary) ; Rogaratinib (Primary) ; Bleomycin; Bleomycin; Bleomycin; Carboplatin; Docetaxel; Fluorouracil; Gemcitabine; Methotrexate; Mitomycin; Paclitaxel
- Indications Head and neck cancer; Hypopharyngeal cancer; Laryngeal cancer; Oropharyngeal cancer; Squamous cell cancer
- Focus Proof of concept; Therapeutic Use
- Acronyms UPSTREAM
- 02 Nov 2023 Status changed from recruiting to active, no longer recruiting.
- 24 Oct 2023 Results of substudy of of the I2 cohort , presented at the 48th European Society for Medical Oncology Congress
- 16 Oct 2023 According to an innate pharma media release, the data from this trial will be presented at the ESMO, 2023, taking place October 20-24 in Madrid, Spain.